WO2000018321A1 - Hydrophilic synthetic blood vessels - Google Patents
Hydrophilic synthetic blood vessels Download PDFInfo
- Publication number
- WO2000018321A1 WO2000018321A1 PCT/US1999/020895 US9920895W WO0018321A1 WO 2000018321 A1 WO2000018321 A1 WO 2000018321A1 US 9920895 W US9920895 W US 9920895W WO 0018321 A1 WO0018321 A1 WO 0018321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibers
- blood vessel
- synthetic
- hydrophilic
- synthetic blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L23/00—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/04—Polysiloxanes
Definitions
- the present invention relates to hydrophilic synthetic blood vessels, i.e., artificial vascular grafts or prostheses, formed from knitted hydrophilic synthetic polymer fibers.
- the present invention also relates to methods of making the synthetic blood vessels and to methods of grafting blood vessels using the same.
- the present invention also relates to implantable medical devices which have at least one surface comprised of the hydrophilic synthetic polymer fibers.
- vascular prosthesis should be substantially impervious to blood loss even in patients that have been heparinized. This may be achieved by minimizing the permeability of the graft to water and biological fluids.
- the prosthesis should also have good surgical handling characteristics, have low thrombogenicity, be free from embolic complications, have no adverse affect on blood, have features that encourage fibroblastic ingrowth, and have intrinsic strength characteristics sufficient to maintain dimensional stability even after a prolonged period in vivo.
- prosthetic grafts remain pliable and preserved in a relatively dry state for extended periods prior to use. This condition enhances the storage life of the graft and thus enhances its convenience to the surgeon and the hospital. It is very important that materials used for artificial organs in general should not cause any toxic, carcinogenic, pyrogenic or allergic effect nor any adverse sue or skin reaction, etc., in the body. In particular, materials of vascular grafts which are used to replace surgically damaged blood vessels should have flexibility as well as anti-thrombogenic properties and be easy to fabricate. Nylon, polyester, polytetrafluoro ethylene polypropylene, polyacrylonitrile, etc. have been used as materials to fabricate vascular grafts.
- Polyester in particular polyethyleneterephthalate (trade name: Dacron), is most widely used as the material of vascular grafts because it is easy to handle and easy to fabricate.
- polyester fibers have been surface-modified with glycoproteins and proteins that interfere with the blood-clotting cascade (see M. Bide,Int. Conf. Exhib., AATCC (1992) 336-42). Polyester fibers have also been impregnated with polysaccharides to increase the adhesion properties of the fibers (see U.S. 5,415,619).
- biomolecules such as proteins, glycoproteins and sugars, etc. have limited stability and may not have the desired durability needed for large-scale production of modified fibers and, especially, stability during storage prior to implantation in patients.
- the present invention is based on the recognition that hydrophilic synthetic fibers which are used to manufacture textiles may be used to prepare knitted synthetic blood vessels (i.e., synthetic vascular or arterial grafts) which have excellent biocompatibility.
- Such synthetic blood vessels will be "friendly" to the recipient, e.g., a human.
- Blood cells and other cells e.g., endothelial cells
- Endothelial cells will be able to line the inventive blood vessels much like natural blood vessels.
- clotting may be prevented in the blood vessels, and the vessel will be a good conduit for blood flow.
- the synthetic blood vessels are expected to have desirable stability and durability properties.
- the synthetic fibers may also be used in other implantable medical devices.
- synthetic blood vessels which provide in one or more, and preferably all, of the following properties: (1) better and faster acceptance of the substrate by the body, (2) quicker and better clotting or sealing the blood vessel from leakage, (3) a better environment for endothelial cell lining formation, (4) a decrease in the incidence of infection, and (5) a decrease in clots forming in the blood supply.
- the object of the invention are also accomplished with an implantable medical device comprising at least one surface comprised of hydrophilic synthetic fibers.
- the synthetic blood vessel of the present invention is a product which is fabricated from hydrophilic synthetic polymer fibers.
- the fibers may be knitted, woven, non-woven, etc.
- the synthetic polymer fiber may be made of a wide variety of polymers, including, polyamides (e.g., nylons), polyesters (e.g., Dacron), polytetrafluoroethylene (PTFE), polypropylene or polyacrylonitrile. Polyamide and polyester fibers are particularly preferred.
- the hydrophilic polymer fiber is fabricated into the form of a tube to produce the inventive synthetic blood vessel. Accordingly, the fibers form the wall of the tube and define a lumen in the center of the tube through which fluid, e.g., blood, can flow.
- the lumen has openings at each end of the tube.
- the length of the tube may vary over a wide range. Preferably, the tube has a length of from 1 mm to 1 m, inclusive of all specific values and subranges therebetween, e.g., 2, 5, 10, 20, 50, 100, 250, 500 and 750 mm.
- the outer diameter of the tube may also vary widely.
- the outer diameter is 2 to 30 mm, inclusive of all specific values and subranges therebetween, e.g., 2, 5, 10, 15, 20 and 25 mm.
- the internal diameter of the lumen may vary from 1 to 29 mm, inclusive of all values and subranges therebetween, e.g., 2, 5, 10, 15, 20 and 25 mm.
- the outer and inner diameters may vary with the type of vascular graft.
- arterial prostheses will generally have an outer diameter from 4 to 20 mm, inclusive of all values and subranges therebetween, whereas venous prostheses will have an outer diameter of 6 to 28 mm, inclusive of all values and subranges therebetween.
- the synthetic blood vessel is preferably in the form of an elongate tube, i.e., the length of the tube is greater than the width of the tube.
- the synthetic blood vessels may be used as artificial arteries, veins or capillaries.
- the fibers may also be used in variety of other implantable medical devices in addition to the synthetic blood vessels described above.
- Such devices contain one or more surfaces composed of the hydrophilic synthetic fibers.
- the surface(s) comprised of the fibers are designed to be in contact with biological fluids, e.g., blood, urine, etc.
- Other implantable medical devices include artificial kidneys, catheters, pacemakers, artificial hearts, artificial bones, artificial joints, etc.
- prosthetic and biomedical devices see Kirk-Othmer Chemical Encyclopedia of Chemical Technology, Volume 20, Fourth Edition, 1993, pp. 351-395, incorporated herein by reference.
- the fibers are preferably of the size used to make athletic weight socks, e.g., having a fiber denier or equivalent thickness unit of about 0.5-3500 denier, preferably 50-200 denier.
- the hydrophilic fibers, preferably spun or continuous filament, can be made into the inventive synthetic blood vessel using conventional techniques and equipment and no modification of the techniques is required.
- hydrophilic synthetic fibers These fibers may be made from fibers which are otherwise hydrophobic by rendering them hydrophilic via a hydrophilizing treatment.
- fibers having hydrophilic properties which may be used in the invention include AKWATEK and AKWADYNE sold by Comfort Technologies, Inc., in which the fibers are treated with lithium cations and borohydride anions. Further, hydrophobic synthetic fibers may be treated with topical hydrophilic wetting agents.
- Suitable fibers are polymers having bonded thereto a hydrophilic copolymer which comprises the reaction product of a primary hydroxylate and a silane as described in U.S. Pat. No. 5,408,012, incorporated herein by reference for a more complete description of preparing these hydrophilic fiber materials.
- MILASE T fibers may also be used to prepare the inventive synthetic blood vessel. These fibers are composed of random ethylene terephthalate/polyethylene glycol (PEG) terephthalate units.
- the surface of the hydrophilic fibers may be treated by any suitable molecular, physical or chemical process or combination thereof, to render the fibers hydrophilic.
- fibers caustically etched with grooves are hydrophilic and transport moisture, and are known in this art.
- fibers having a modified cross-section, i.e., irregular, non-oval, fluted or grooved fibers are known hydrophilic fibers and may be used to prepare the synthetic blood vessel of the present invention.
- Copolymer fibers prepared by combining the extrusion of synthetic fibers and fibers containing absorbing components such as poly(ethylene glycol) are acceptable for use in the present invention.
- COOLMAX fibers are commercially available under the tradenames COOLMAX by DuPont (non-oval fiber) and HYDROPHIL by Allied (copolymer extrusion with poly (ethylene glycol) fibers).
- COOLMAX fibers have a relatively large surface area in relation to volume. In addition, these fibers have four channels along their respective longitudinal dimensions to encourage the wicking of fluids.
- Hollow synthetic fibers may be hydrophilic and are capable of transporting water through the capillary fibers. Such hollow fibers are known and available commercially, for example, THERMAX fibers available from DuPont.
- Hydrophobic fibers such as nylon and polyester, which have been rendered hydrophilic by chemical surface treatment are particularly preferred for manufacturing the synthetic blood vessel of the present invention.
- Suitable chemical processes are described, for example, in U.S. Pat. No. 4,705,831; U.S. Pat. No. 4,726,968; U.S. Pat. No. 4,743,267; U.S. Pat. No. 4,672,005; U.S. Pat. No. 4,563,507; U.S. Pat. No. 4,806,125; U.S. Pat. No. 5,154,727; and U.S. Patent Application 08/710,715, filed September 20, 1996 (Attorney Docket No. 1876-0106-40).
- the hydrophobic synthetic polymer fiber substrate is contacted with an aqueous mixture containing a water-soluble vinyl monomer and a hydrophobic vinyl monomer at a temperature of between about 40°-100°C. Polymerization of the water-soluble monomer is then initiated by a chemical or physical initiator to form a vinyl polymer evenly disposed on the substrate fiber.
- Suitable water-soluble vinyl monomers and hydrophobic monomers are described in U.S. Pat. No. 4,672,005.
- the fibers used to prepare the inventive blood vessels are suitable for the manufacture of textiles, and are preferably completely synthetic.
- This refers to fibers that are composed entirely of man-made materials, and not materials which occur in or are isolated from humans. Accordingly, in this embodiment, excluded are substrate fibers which have been modified with biomolecules, such as amino acids, peptides, polypeptides, proteins, glycopeptides, glycoproteins and sugars (e.g., oligosaccharides (and derivatives thereof) or sugar monomers).
- biomolecules such as amino acids, peptides, polypeptides, proteins, glycopeptides, glycoproteins and sugars (e.g., oligosaccharides (and derivatives thereof) or sugar monomers).
- the hydrophilic synthetic fibers used to prepare the inventive synthetic blood vessel should effectively transport blood.
- the hydrophilic fiber should wick water at a rate of at least 1/10 inch per initial min., more preferably at least 1/2 inch per initial min., in a standard wicking test, for example the standard TDI No. 4 (Textile Distributors Institute) test.
- the fabric should wick whole human blood in the vertical absorption test described below at least 0.25 inches in 30 seconds, preferably at least 0.75 inches, more preferably at least 1 inch and most preferably at least 1.2 inches, in 30 seconds.
- the fabric should have a drop time in the drop test described below of at most 220 seconds, preferably at most 100 seconds, more preferably at most 50 seconds, and, most preferably, at most ten seconds.
- the fabric may have even lower drop times, such as at most 5, 3, 2 or 1 second.
- Hydrophilic fabrics suitable for use in the present invention can be readily determined by one having ordinary skill in this art.
- Vertical wicking of hydrophilic fibers which maybe used in the present invention can be determined by the following procedures.
- a piece of fabric measuring 1x6 inches made from the fibers is prepared.
- a non-indelible ink line is drawn vertically through the middle of the fabrics such that the path of transported water is more visible.
- the fabric is held vertically and immersed to a depth of 1/2 inch in a 200 milliliter beaker containing 150 milliliters of water. After 30 seconds of elapsed time, the vertical distance traveled by the transported water is measured.
- the inventive synthetic blood vessel may be used to graft blood vessels according to procedures which are routine and well-known to those of ordinary skill in this art. Briefly, blood vessels (e.g., arteries, veins or capillaries) by contacting a first blood vessel with one end of the synthetic blood vessel and contacting a second blood vessel with the other end of the synthetic blood vessel, thereby grafting the first and second blood vessels.
- blood vessels e.g., arteries, veins or capillaries
- This test measures the hydrophilicity, i.e., power or attraction of the substrate for blood, by how quickly it causes the reflection from the blood drop to disappear.
- This test is performed by dropping a drop of blood from a dropper from a height of 1/2" onto a 3" x 3" horizontally laid square of the fabric and recording the time for the drop to be absorbed such that there is no reflection from the drop of blood.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Transplantation (AREA)
- Life Sciences & Earth Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU63867/99A AU6386799A (en) | 1998-09-28 | 1999-09-28 | Hydrophilic synthetic blood vessels |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16131498A | 1998-09-28 | 1998-09-28 | |
US09/161,314 | 1998-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000018321A1 true WO2000018321A1 (en) | 2000-04-06 |
Family
ID=22580682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/020895 WO2000018321A1 (en) | 1998-09-28 | 1999-09-28 | Hydrophilic synthetic blood vessels |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6386799A (en) |
WO (1) | WO2000018321A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572288B2 (en) | 2001-07-20 | 2009-08-11 | Microvention, Inc. | Aneurysm treatment device and method of use |
US8715312B2 (en) | 2001-07-20 | 2014-05-06 | Microvention, Inc. | Aneurysm treatment device and method of use |
US9023094B2 (en) | 2007-06-25 | 2015-05-05 | Microvention, Inc. | Self-expanding prosthesis |
US9622753B2 (en) | 2001-07-20 | 2017-04-18 | Microvention, Inc. | Aneurysm treatment device and method of use |
US10058330B2 (en) | 2011-05-11 | 2018-08-28 | Microvention, Inc. | Device for occluding a lumen |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5415619A (en) * | 1989-12-13 | 1995-05-16 | Korea Research Institute Of Chemical Tech. | Method of manufacturing a vascular graft impregnated with polysaccharide derivatives |
-
1999
- 1999-09-28 WO PCT/US1999/020895 patent/WO2000018321A1/en active Application Filing
- 1999-09-28 AU AU63867/99A patent/AU6386799A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5415619A (en) * | 1989-12-13 | 1995-05-16 | Korea Research Institute Of Chemical Tech. | Method of manufacturing a vascular graft impregnated with polysaccharide derivatives |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572288B2 (en) | 2001-07-20 | 2009-08-11 | Microvention, Inc. | Aneurysm treatment device and method of use |
US8562667B2 (en) | 2001-07-20 | 2013-10-22 | Microvention, Inc. | Aneurysm treatment device and method of use |
US8715312B2 (en) | 2001-07-20 | 2014-05-06 | Microvention, Inc. | Aneurysm treatment device and method of use |
US9539122B2 (en) | 2001-07-20 | 2017-01-10 | Microvention, Inc. | Aneurysm treatment device and method of use |
US9622753B2 (en) | 2001-07-20 | 2017-04-18 | Microvention, Inc. | Aneurysm treatment device and method of use |
US9023094B2 (en) | 2007-06-25 | 2015-05-05 | Microvention, Inc. | Self-expanding prosthesis |
US10058330B2 (en) | 2011-05-11 | 2018-08-28 | Microvention, Inc. | Device for occluding a lumen |
Also Published As
Publication number | Publication date |
---|---|
AU6386799A (en) | 2000-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6024918A (en) | Method for attachment of biomolecules to surfaces of medical devices | |
CA1240805A (en) | Vascular prosthesis | |
US6143354A (en) | One-step method for attachment of biomolecules to substrate surfaces | |
US5584875A (en) | Method for making vascular grafts | |
JP3504389B2 (en) | Tubular graft impregnated with collagen sealant containing heparin | |
US5171261A (en) | Vascular prosthesis, manufacturing method of the same, and substrate for vascular prothesis | |
US5578073A (en) | Thromboresistant surface treatment for biomaterials | |
RU2670970C1 (en) | Vascular prosthesis | |
DE10004884A1 (en) | Immobilization of biomolecules on medical devices included converting surface amide groups to amine groups by treatment with hypohalite and hydroxide ions | |
EP0947205A2 (en) | Method for making biocompatible medical article | |
JP2006524117A (en) | Arteriovenous grafts with the ability to seal themselves quickly after surgery | |
US20050107868A1 (en) | Scaffold for tissue engineering, artificial blood vessel, cuff, and biological implant covering member | |
RU2655773C2 (en) | Antithrombotic artificial blood vessel | |
WO2010106943A1 (en) | Medical material for in vivo implantation containing softening agent and/or moisturizing agent, method for controlling content of softening agent and/or moisturizing agent in the medical material, and method for producing the medical material for in vivo implantation | |
Guidoin et al. | Polyester prostheses as substitutes in the thoracic aorta of dogs. I. Evaluation of commercial prostheses | |
EP0246638A2 (en) | Biologically modified synthetic grafts | |
WO2000018321A1 (en) | Hydrophilic synthetic blood vessels | |
EP0781089A4 (en) | Thromboresistant surface treatment for biomaterials | |
CN113577395B (en) | Hydrogel artificial blood vessel and preparation method thereof | |
JPS63115554A (en) | Artificial blood vessel excellent in pseudo-endothelium forming property | |
CA2484012C (en) | Scaffold for tissue engineering, artificial blood vessel, cuff, and biological implant covering member | |
JP2568100B2 (en) | Medical tubular article with excellent antithrombogenicity and method for producing the same | |
CA1092303A (en) | Flexible vascular graft of polymeric material with internal porous surface | |
Noishiki | A new in vivo evaluation method of antithrombogenicity using a polymer-coated suture inserted into the peripheral vein | |
JPH04146763A (en) | Gelatinous material sticking method to medical substrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 63867 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
REF | Corresponds to |
Ref document number: 10082678 Country of ref document: DE Date of ref document: 20021121 Format of ref document f/p: P |